Related references
Note: Only part of the references are listed.Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy
Mike Sathekge et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT
Hendrik Rathke et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Mike Sathekge et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Harmonization of US, European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible?
Sally W. Schwarz et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Melanocortin 1 Receptor-Targeted α-Particle Therapy for Metastatic Uveal Melanoma
Narges K. Tafreshi et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
Michael J. Morris et al.
EUROPEAN JOURNAL OF CANCER (2019)
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma
Mengshi Li et al.
MOLECULAR PHARMACEUTICS (2019)
Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma
Sophie Poty et al.
CLINICAL CANCER RESEARCH (2019)
Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives
Maarten J. van der Doelen et al.
CLINICAL GENITOURINARY CANCER (2019)
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice
Sabina Dizdarevic et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma
Leszek Krolicki et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model
James M. Kelly et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform
Abigail E. Besemer et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2018)
Exploration of a F(ab′)2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy
Diane E. Milenic et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2018)
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
Lorenzo Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2018)
The inverse electron-demand Diels-Alder reaction as a new methodology for the synthesis of 225Ac-labelled radioimmunoconjugates
S. Poty et al.
CHEMICAL COMMUNICATIONS (2018)
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer
Neal D. Shore et al.
CLINICAL GENITOURINARY CANCER (2018)
Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study
Michael E. Autenrieth et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer
Angelo Castello et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model
Yasuhiro Ohshima et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
Sabina Dizdarevic et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with Bi-213-substance P analogue
Leszek Krolicki et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models
Benjamin B. Kasten et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617:Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models
Benjamin B. Kasten et al.
NUCLEAR MEDICINE AND BIOLOGY (2018)
Therapeutic Effect of α-Emitting 224Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer
Sara Westrom et al.
TRANSLATIONAL ONCOLOGY (2018)
Structure and properties of DOTA-chelated radiopharmaceuticals within the 225Ac decay pathway
Artem R. Khabibullin et al.
MEDCHEMCOMM (2018)
Targeted cancer cell ablation in mice by an alpha-particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B
Huizi Keiko Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
In vivo Evaluation of [225Ac]Ac-DOTAZOL for α-Therapy of Bone Metastases
Nina Pfannkuchen et al.
CURRENT RADIOPHARMACEUTICALS (2018)
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Alfred Morgenstern et al.
CURRENT RADIOPHARMACEUTICALS (2018)
Radium and other alpha emitters in prostate cancer
Oliver Sartor et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2018)
Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure
M. E. Autenrieth et al.
UROLOGE (2017)
Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure
M. E. Autenrieth et al.
UROLOGE (2017)
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3-Targeted Liposomes
Anirudh Sattiraju et al.
MOLECULAR CANCER THERAPEUTICS (2017)
B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models
Benjamin B. Kasten et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
Bystander signaling via oxidative metabolism
Humaira Aziz Sawal et al.
ONCOTARGETS AND THERAPY (2017)
Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma
Urs B. Hagemann et al.
ONCOTARGET (2017)
IL13RA2 targeted alpha particle therapy against glioblastomas
Anirudh Sattiraju et al.
ONCOTARGET (2017)
Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model
Jessie R. Nedrow et al.
EJNMMI RESEARCH (2017)
More α Than β for Prostate Cancer?
Wolfgang P. Fendler et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy
Nikki A. Thiele et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
Charles Zhu et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
S. Nilsson et al.
ANNALS OF ONCOLOGY (2016)
Large scale accelerator production of 225AC: Effective cross sections for 78-192 MeV protons incident on 232Th targets
J. R. Griswold et al.
APPLIED RADIATION AND ISOTOPES (2016)
Re: 225Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate Cancer
Boris Hadaschik
EUROPEAN UROLOGY (2016)
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial
Christopher Parker et al.
EUROPEAN UROLOGY (2016)
225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Site-Specifically Labeled Immunoconjugates for Molecular Imaging-Part 2: Peptide Tags and Unnatural Amino Acids
Pierre Adumeau et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
Site-Specifically Labeled Immunoconjugates for Molecular Imaging-Part 1: Cysteine Residues and Glycans
Pierre Adumeau et al.
MOLECULAR IMAGING AND BIOLOGY (2016)
The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic
Mehran Makvandi et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
Radioimmunotherapy for Treatment of Acute Leukemia
Caroline Bodet-Milin et al.
SEMINARS IN NUCLEAR MEDICINE (2016)
Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigenspecific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation
Anthony S. Malamas et al.
ONCOTARGET (2016)
Preliminary Therapy Evaluation of 225Ac-DOTA-c (RGDyK) Demonstrates that Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization
Darpan N. Pandya et al.
THERANOSTICS (2016)
Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
Ho Sze Chan et al.
EJNMMI RESEARCH (2016)
The Radiochemical and Radiopharmaceutical Applications of Radium
Matthew Gott et al.
OPEN CHEMISTRY (2016)
Recurrent Bleeding in Hemorrhagic Moyamoya Disease : Prognostic Implications of the Perfusion Status
Kyung-Il Jo et al.
JOURNAL OF KOREAN NEUROSURGICAL SOCIETY (2016)
Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues
Xiuling Li et al.
BIOCONJUGATE CHEMISTRY (2015)
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model
Damian J. Green et al.
BLOOD (2015)
Fractionated intravesical radioimmunotherapy with 213Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma
Julia Fazel et al.
CANCER BIOLOGY & THERAPY (2015)
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer
Hossein Jadvar et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2015)
Cerenkov Luminescence Imaging for Radiation Dose Calculation of a 90Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist
Christian Lohrmann et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Encapsulation of α-Particle-Emitting 225Ac3+ Ions Within Carbon Nanotubes
Michael L. Matson et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies
E. David Crawford et al.
JOURNAL OF UROLOGY (2015)
Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease
Diane E. Milenic et al.
MABS (2015)
Prospective carriers of 223Ra for targeted alpha particle therapy
J. Kozempel et al.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY (2015)
Application of Pb-212 for Targeted alpha-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation
Kwon Yong et al.
AIMS MEDICAL SCIENCE (2015)
A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters?
Robin M. De Kruijff et al.
PHARMACEUTICALS (2015)
Single-dose anti-cd138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model
Nolwenn Fichou et al.
FRONTIERS IN MEDICINE (2015)
Molecular Targeted α-Particle Therapy for Oncologic Applications
Thaddeus J. Wadas et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2014)
A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease
Robert Coleman et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients
Ruby F. Meredith et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
LnPO4 Nanoparticles Doped with Ac-225 and Sequestered Daughters for Targeted Alpha Therapy
Mark F. McLaughlin et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2xAnti-HSG Bispecific Antibody and a 177Lu-Labeled Peptide
Catharina M. van Rij et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
Amir Sabet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
C. Kratochwil et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
Matthias D'Huyvetter et al.
EXPERT OPINION ON DRUG DELIVERY (2014)
RADIATION SAFETY CONSIDERATIONS FOR THE USE OF 223 RaCl2 DE IN MEN WITH CASTRATION- RESISTANT PROSTATE CANCER
Lawrence T. Dauer et al.
HEALTH PHYSICS (2014)
Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for α-Particle Radioimmunotherapy of Cancer
William F. Maguire et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab
Ruby Meredith et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
Peter Hoskin et al.
LANCET ONCOLOGY (2014)
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor et al.
LANCET ONCOLOGY (2014)
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
E. M. P. Poels et al.
MOLECULAR PSYCHIATRY (2014)
The iQID camera: An ionizing-radiation quantum imaging detector
Brian W. Miller et al.
NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT (2014)
Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy
S. Gouard et al.
NUCLEAR MEDICINE AND BIOLOGY (2014)
Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific 64Cu-DOTA conjugation
Richard Tavare et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2014)
Role of neuroimaging in drug development
Bikash Medhi et al.
REVIEWS IN THE NEUROSCIENCES (2014)
The potential and hurdles of targeted alpha therapy - clinical trials and beyond
Jorgen Eigqvist et al.
FRONTIERS IN ONCOLOGY (2014)
Targeted alpha anticancer therapies: update and future prospects
Barry J. Allen et al.
BIOLOGICS-TARGETS & THERAPY (2014)
Renal Brush Border Enzyme-Cleavable Linkages for Low Renal Radioactivity Levels of Radiolabeled Antibody Fragments
Hiromichi Akizawa et al.
BIOCONJUGATE CHEMISTRY (2013)
Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
Johnnie J. Orozco et al.
BLOOD (2013)
Production of [211At]-Astatinated Radiopharmaceuticals and Applications in Targeted α-Particle Therapy
Francois Guerard et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
Sten Nilsson et al.
CLINICAL GENITOURINARY CANCER (2013)
Targeted α-Particle Therapy of Bone Metastases in Prostate Cancer
Hossein Jadvar et al.
CLINICAL NUCLEAR MEDICINE (2013)
Coordination Chemistry with f-Element Complexes for an Improved Understanding of Factors That Contribute to Extraction Selectivity
Anne E. V. Gorden et al.
INORGANIC CHEMISTRY (2013)
213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma
Michel Cherel et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery
J. Justin Mulvey et al.
NATURE NANOTECHNOLOGY (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Methodology for labeling proteins and peptides with lead-212 (212Pb)
Kwamena E. Baidoo et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
Development and validation of RAYDOSE: a Geant4-based application for molecular radiotherapy
S. Marcatili et al.
PHYSICS IN MEDICINE AND BIOLOGY (2013)
Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy
Mark F. McLaughlin et al.
PLOS ONE (2013)
Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb
Vincent Boudousq et al.
PLOS ONE (2013)
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211 At-mAb
Sophie E. Eriksson et al.
EJNMMI RESEARCH (2013)
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
Harrison et al.
Cancer Management and Research (2013)
Improvement of radioimmunotherapy using pretargeting
Eric Frampas et al.
FRONTIERS IN ONCOLOGY (2013)
Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging
Alain P. Pecking et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
Optimizing Cancer Treatments to Induce an Acute Immune Response: Radiation Abscopal Effects, PAMPs, and DAMPs
Charles M. Ludgate
CLINICAL CANCER RESEARCH (2012)
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
S. Nilsson et al.
EUROPEAN JOURNAL OF CANCER (2012)
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis
Markus Essler et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides
N. L. Ackerman et al.
PHYSICS IN MEDICINE AND BIOLOGY (2012)
Quantitative Modeling of Cerenkov Light Production Efficiency from Medical Radionuclides
Bradley J. Beattie et al.
PLOS ONE (2012)
Alpha Particle Emitter Radiolabeled Antibody for Metastatic Cancer: What Can We Learn from Heavy Ion Beam Radiobiology?
Hong Song et al.
ANTIBODIES (2012)
LaPO4 Nanoparticles Doped with Actinium-225 that Partially Sequester Daughter Radionuclides
Jonathan Woodward et al.
BIOCONJUGATE CHEMISTRY (2011)
Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
Damian Wild et al.
CANCER RESEARCH (2011)
177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi
Christof Seidl et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma
Barry J. Allen et al.
IMMUNOTHERAPY (2011)
Clinical radioimmunotherapy-the role of radiobiology
Jean-Pierre Pouget et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody
J. Schwartz et al.
PHYSICS IN MEDICINE AND BIOLOGY (2011)
Integrin Targeted Imaging and Therapy
Xiaoyuan Chen
THERANOSTICS (2011)
Experimental alpha-particle radioimmunotherapy of breast cancer using Th-227-labeled p-benzyl-DOTA-trastuzumab
Nasir Abbas et al.
EJNMMI RESEARCH (2011)
Production of 225Ac and 223Ra by Irradiation of Th with Accelerated Protons
B. L. Zhuikov et al.
RADIOCHEMISTRY (2011)
Astatine-211: Production and Availability
Michael R. Zalutsky et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Chemical and Radiochemical Considerations in Radiolabeling with alpha-Emitting Radionuclides
D. Scott Wilbur
CURRENT RADIOPHARMACEUTICALS (2011)
Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
David A. Scheinberg et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Targeted Alpha Therapy with Bi-213
Alfred Morgenstern et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Tumor heterogeneity: Causes and consequences
Andriy Marusyk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2010)
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
Steven I. Park et al.
BLOOD (2010)
Improved Efficacy of α-Particle-Targeted Radiation Therapy
Diane E. Milenic et al.
CANCER (2010)
Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors
Freddy E. Escorcia et al.
CANCER RESEARCH (2010)
Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
Todd L. Rosenblat et al.
CLINICAL CANCER RESEARCH (2010)
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate Th-227-rituximab
Jostein Dahle et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
Alessandro Ruggiero et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2010)
The α-Camera: A Quantitative Digital Autoradiography Technique Using a Charge-Coupled Device for Ex Vivo High-Resolution Bioimaging of α-Particles
Tom Back et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
George Sgouros et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Cerenkov Luminescence Imaging of Medical Isotopes
Alessandro Ruggiero et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice
Jorgen Elgqvist et al.
JOURNAL OF ONCOLOGY (2010)
Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211
Hirohisa Nakamae et al.
CANCER RESEARCH (2009)
Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y
Hong Song et al.
CANCER RESEARCH (2009)
Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models BY 213Bilabeled Multiple Targeted α Radioimmunoconjugates
Yong Li et al.
CLINICAL CANCER RESEARCH (2009)
A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
James R. Berenson et al.
CLINICAL CANCER RESEARCH (2009)
Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2-A Phase I Study
Hakan Andersson et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Intravesical α-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice
Birgit Pfost et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide 213Bi-DTPA-[F3]2 into the Nucleus of Tumor Cells
Enken Drecoll et al.
PLOS ONE (2009)
Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAb
Birgit Pfost et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Alpha-particles for targeted therapy
George Sgouros
ADVANCED DRUG DELIVERY REVIEWS (2008)
Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications
Matthias Miederer et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases
Min-Yuan Chang et al.
BIOCONJUGATE CHEMISTRY (2008)
Preclinical evaluation of the α-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors
Matthias Miederer et al.
CLINICAL CANCER RESEARCH (2008)
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the α-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies
Matthew K. Robinson et al.
CLINICAL CANCER RESEARCH (2008)
The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer
Michael J. Willhauck et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
203Pb-labeled α-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection
Yubin Miao et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Targeted radionuclide therapy
Lawrence E. Williams et al.
MEDICAL PHYSICS (2008)
Three-dimensional imaging-based radiobiological dosimetry
George Sgouros et al.
SEMINARS IN NUCLEAR MEDICINE (2008)
Clinical experience with alpha-particle-emitting At-211: Treatment of recurrent brain tumor patients with At-211-labeled chimeric antitenascin monoclonal antibody 81C6
Michael R. Zalutsky et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer
Sebastian Knoer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Enhanced retention of the α-particle-emitting daughters of actinium-225 by liposome carriers
Stavroula Sofou et al.
BIOCONJUGATE CHEMISTRY (2007)
Targeted α-particle radiotherapy with 211At-labeled monoclonal antibodies
Michael R. Zalutsky et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice
Stig Palm et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes
Michael R. McDevitt et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Interim analysis of oxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma
Chand Raja et al.
CANCER BIOLOGY & THERAPY (2007)
Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry
Andrew R. Prideaux et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma
Junping Cheng et al.
LARYNGOSCOPE (2007)
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1
Meili Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease
Diane E. Milenic et al.
CLINICAL CANCER RESEARCH (2007)
High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra:: Adjuvant or alternative to conventional modalities?
Oyvind S. Bruland et al.
CLINICAL CANCER RESEARCH (2006)
Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P
Stefan Kneifel et al.
CLINICAL CANCER RESEARCH (2006)
213Bi-[DOTA0,Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model
JP Norenberg et al.
CLINICAL CANCER RESEARCH (2006)
Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody
S Bloechl et al.
CLINICAL CANCER RESEARCH (2005)
Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator
FM Su et al.
NUCLEAR MEDICINE AND BIOLOGY (2005)
α-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2
DE Milenic et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Renal tubulointerstitial changes after internal irradiation with α-particle-emitting actinium daughters
JS Jaggi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Melanoma therapy via peptide-targeted α-radiation
YB Miao et al.
CLINICAL CANCER RESEARCH (2005)
First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases
S Nilsson et al.
CLINICAL CANCER RESEARCH (2005)
OEDIPE:: A personalized dosimetric tool associating voxel-based models with MCNPX
S Chiavassa et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Cancer radioimmunotherapy with alpha-emitting nuclides
O Couturier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Synthesis and metal complexation properties of Ph-DTPA and Ph-TTHA: novel radionuclide chelating agents for use in nuclear medicine
SG Gouin et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2005)
Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody
D Milenic et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
MicroPET imaging of breast cancer αv-integrin expression with 64Cu-labeled dimeric RGD peptides
XY Chen et al.
MOLECULAR IMAGING AND BIOLOGY (2004)
Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids:: Efficacy versus HER2/neu expression
ÅM Ballangrud et al.
CLINICAL CANCER RESEARCH (2004)
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of α-emitting atomic nanogenerators targeting disialo-ganglioside GD2
M Miederer et al.
CLINICAL CANCER RESEARCH (2004)
MicroPET and autoradiographic imaging of breast cancer alpha(v)-integrin expression using F-18- and Cu-64-labeled RGD peptide
XY Chen et al.
BIOCONJUGATE CHEMISTRY (2004)
Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N′,N,N′-tetraacetic acid for radiolabeling proteins
LL Chappell et al.
NUCLEAR MEDICINE AND BIOLOGY (2003)
GEANT4-a simulation toolkit
S Agostinelli et al.
NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT (2003)
Engineered antibodies
Peter J. Hudson et al.
NATURE MEDICINE (2003)
A systematic overview of radiation therapy effects in skeletal metastases
U Falkmer et al.
ACTA ONCOLOGICA (2003)
Design and synthesis of 225Ac radioimmunopharmaceuticals
MR McDevitt et al.
APPLIED RADIATION AND ISOTOPES (2002)
Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. site-specific conjugation of DOTA-peptides to a cys-diabody
L Li et al.
BIOCONJUGATE CHEMISTRY (2002)
Targeted at particle immunotherapy for myeloid leukemia
JG Jurcic et al.
BLOOD (2002)
Pretargeting radioinimunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213
ML Zhang et al.
BLOOD (2002)
Tumor therapy with targeted atomic nanogenerators
MR McDevitt et al.
SCIENCE (2001)
Advancements in cancer therapy with alpha-emitters: A review
SK Imam
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
The development of the α-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications
S Hassfjell et al.
CHEMICAL REVIEWS (2001)
General aspects of the cellular response to low- and high-LET radiation
JP Pouget et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin
S Demartis et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
DPM, a fast, accurate Monte Carlo code optimized for photon and electron radiotherapy treatment planning dose calculations
J Sempau et al.
PHYSICS IN MEDICINE AND BIOLOGY (2000)
Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for 225Ac radioimmunotherapy applications
LL Chappell et al.
BIOCONJUGATE CHEMISTRY (2000)
Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes Pb-203 and Pb-212
LL Chappell et al.
NUCLEAR MEDICINE AND BIOLOGY (2000)
Astatine-211-labeled radiotherapeutics: An emerging approach to targeted alpha-particle radiotherapy
MR Zalutsky et al.
CURRENT PHARMACEUTICAL DESIGN (2000)
Share Paper
